Welcome to Chiesi
SVERIGE
Chiesi conducts research within asthma and COPD, the most common respiratory diseases
Chiesi is fully committed to the work of improving the care and quality of life of everybody suffering from respiratory diseases such as asthma or chronic obstructive...
CHIESI – A RESULT OF SUCCESSFUL RESEARCH WITHIN NEONATOLOGY
A normal delivery takes place between weeks 37 and 42 of a pregnancy. By that time, the foetus is fully formed and sufficiently developed to be able to adapt to extra-uterine life. Sometimes delivery takes place before the...
RARE DISEASES
Rare diseases, or uncommon diagnoses, is a generic term for a range of diseases that affect very few people. The European criteria for a disease or diagnosis to be designated as uncommon is that it is present in a maximum of 1 in 2,000 people and leads to disability. In...
Kidney and liver failure – organ transplants
The kidneys perform a number of physiological functions, ranging from filtering the blood and removing waste products to maintaining the electrolyte balance and regulating the production of red blood cells via the...
-
Chiesi in the Nordic region – rapid and sustainable growth Our Nordic subsidiaries are part of the international, family-owned pharmaceutical group Chiesi Group and are pharmaceutical companies operating within research and development, as well as manufacture of innovative drugs....
Surfactant – groundbreaking for preterm babies
The Nordic roots extend a long way back in time. It all started in the 1980s when two researchers at the Karolinska Institute in Stockholm, Bengt Robertson and Tore Curstedt, succeeded in extracting surfactant from pig lungs....
Chiesi develops and distributes pharmaceuticals in over 100 countries and has 30 international companies in Europe, America, Asia and Africa. Today, Chiesi is one of the world's leading pharmaceutical companies in the...
Research, innovation and development are the driving forces for Chiesi's growth. Chiesi opened a new research and development centre at Karolinska Institute's Campus in Solna in spring 2020. Chiesi invests continuously in research and development, with the focus on innovative drugs within four...
We have a strong pipeline for respiratory diseases, neonatology, special care and rare diseases. Please find more information at Research and development/pipeline
Thanks to four international research facilities, we can maintain a high level in the development and manufacture of innovative new drugs. Our plants are located in Paris (France), Rockville (USA), Chippenham (England) and...
There are currently no vacant positions. However, you are welcome to send in your CV for future opportunities.
For more information, please contact Olav Fromm, Managing Director, tel 08-753...
You are always welcome to contact us by telephone or email if you have questions or wish to know more about any medicine.
Local Press Officer:
Annelie Barkelund, PA and external communication...
What are cookies?
Cookies are small information files that – when you connect to a Web site – are transferred to your computer and stored in association with the files used by the browser.
Why use...
This homepage was edited and produced by Dynamic Mind.
-
You are always welcome to contact us by telephone or email if you have questions or wish to know more about any medicine.
However, in accordance with Swedish law, we cannot give out any information about our medicines to patients.
The following must be used for submitting...
Chiesi Farmaceutici has a system of pharmacovigilance in order to assume liability for our products (whether marketed or under clinical development) and to take appropriate actions when necessary. We ensure that all information relevant to patient safety and the risk-benefit ratio...
Here you can find our declarations of value transfers from Chiesi to health care professionals (HCP) and health care organisations (HCO).
-
Terms of Service
March 2016
Approval
By accessing and using this website, you agree to apply the following terms and conditions governing the relationship between Chiesi Pharma AB ( "Chiesi") and you, the (“User") regarding the use of these web pages...
Chiesi Nordic, a fast-growing pharmaceutical company
Chiesi is one of Europe's leading pharmaceutical companies, investing intensively in research and development (R&D). It is advances in research within our principal areas - respiratory diseases, neonatology, rare diseases and...
Chiesi is one of Europe's leading pharmaceutical companies, investing intensively in research and development (R&D). It is advances in research within our principal areas - respiratory diseases, neonatology, rare diseases...
As a Benefit Corporation and a B Corp certified company, sustainability is an essential part of our business. This is why we have decided, starting in 2019, to include in one single publication financial, social and environmental data. The Annual & Sustainability Report 2020 provides a...
1. Scope of the privacy policy
1.1 Below is a description of how Chiesi Pharma AB, company registration number 556827-5746, with the address Klara Norra Kyrkogata 34, 111 22, Stockholm, (“Chiesi”, “us” or...
With people in focus
We want to be a positive force. Having good relations with society and our employees and taking responsibility for the environment and our surroundings are therefore our top priorities. We apply our values on a daily basis in the work we perform and in relations with...
-
-
Sustainability issues are central to Chiesi. Since the outset, care for people in the form of patients, employees and the local society, has been a fundamental value.
Chiesi has developed and expanded its sustainability management in order to be a...
We Act - We Actively Care for Tomorrow, is an expression of Chiesi's desire to promote sustainable conduct. We Act is a group-wide programme with initiatives for co-workers regarding the environment and the local community, for the benefit of both Chiesi and those affected by Chiesi. (Read our...
Chiesi's aim is to contribute to economic, social, environmental and cultural sustainability in society. The basis is a belief in the principal of ”shared value”; to create a return for both the company and for society.
To ensure a positive impact on society, a...
Within the four focus areas of People, Patient, Planet and Partnerships, there are specific sustainability goals, undertakings for the next few years. The goals are under constant evaluation and adaptation. They express an intention, and they are ambitious. In addition to this, the Chiesi...
A pharmaceutical company with sustainability in focus
We are passionate about improving and raising people’s quality of life.
Chiesi is a B-Corp certified company, which means that we want our profits to come from creating increased value for everyone,...
An opportunity for a career in a global setting
For those interested in, or with previous experience from the pharmaceutical industry, Chiesi offers the opportunity for further career development, enabling you to enhance your competences by working directly on complex projects requiring...
Here we gather information regarding education and seminars, you can also order material and book digital or personal meetings with our local representatives. Our ambition is to help you do a good job even better.
-
-
Register to the Webinar
Agenda
Chairman: L. Fabbri
16.00-16.10 Welcome and Keynote Address – L.Fabbri
16.10-14.35 Unmet needs in COPD:how to address them? – L. Fabbri
16.35-17.00 Focus on treatment: role of GOLD guidelines,...
-
Chiesi is one of Europe's leading pharmaceutical companies. The company was founded in Italy in 1935 and today offers drugs in over 65 countries. We have been in the Nordic region since 2013.
Our culture belongs to the brave and the curious. At Chiesi we focus on finding innovative solutions and embracing new challenges. Every choice we make is driven by the will to generate a positive impact both on our community and our planet
Everyone of us is different, everyone of us is Chiesi.
Chiesi Nordic is committed to put our people at the centre. We strive to hire a diverse work force at all levels of our business, as it is our belief that a mix of different backgrounds and personalities form...
Leber's hereditary optic neuropathology (LHON) is an uncommon, hereditary mitochondrial disease. 1 in 50,000 individuals are estimated to have the disease in the Nordic region, and 1 in 9,000 are carriers. Only women can transmit the predisposition on to the next generation. Not all carriers...
Alpha Mannosidosis is a rare genetic disease that usually emerges in childhood. Persons who have the disease are completely or partially deficient in the enzyme alpha-D-mannosidase, which means that substances which contain the carbohydrate mannose are stored in the cells instead of being broken...
Nephropathic Cystinosis is a rare genetic disease which occurs in approx. 1/100 000-200,000 live births. The disease is characterised by accumulation of the amino acid cystins within lysosomes in the cells, leading to damage in many organs and tissues. It is usually detected in early childhood...
-
Chiesi is B-corp certified which is proof of high social and environmental standards, a recognition of high social and environmental standards. It is an achievement to be proud of, and yet one that feels natural: caring for others lies at the root of health science and has always been at the...
In Chiesi Pharma 2024 sustainability report you find our actions from the Nordic organisation and in the corporate sustainability report you find the actions from the global organisation.
The Nordic sustainability report focuses on Chiesi's sustainability footprint and...
When we, late 2019, approved our sustainability plan 2019–2022, we thought we had aimed high. In order for us to implement the plan we divided all employees into sustainability groups (which we called “sustainability pathways”). I think it was only then that I...
-
Varför gör inte patienten som vi säger?
Hur får vi patienten att ta ansvar för sin behandling?
Onsdagen den 6...
Under 2021 erbjuder Chiesi dig som möter astma-/KOL-patienter att delta i en utbildningsserie om fyra fristående digitala liveföreläsningar med astma/KOL-sjuksköterskan Claire Johnson. Syftet är att ge dig uppdatering och fördjupning inom...
-
PRIVACY NOTICE
This privacy notice is provided by Chiesi Farmaceutici S.p.A., including its affiliates (together “Chiesi Group“ or “Chiesi”) in compliance with the applicable privacy regulations and is aimed at informing...
-
Our partnerships
For us at Chiesi Pharma, partnerships are important. We look for relationships characterized by mutual understanding of the sustainability challenges we face. We also think it is important to be able to disclose the...
FOR INNOVATIVE TECHNOLOGIES TO TREAT RARE METABOLIC DISEASES
Collaborating with Chiesi
We look forward to hearing from researchers and physician-scientists who are keen to...
FOR INNOVATIVE TECHNOLOGIES TO TREAT RARE METABOLIC DISEASES
This represents a Request for Proposals (RFP) from Chiesi Farmaceutici S.p.A...
d
Epidermolysis Bullosa (EB) är en ärftlig, sällsynt och svår hudsjukdom. Sjukdomen orsakar bräcklighet och blåsor i huden. I svåra fall påverkas flera organ med ärrbildning och förkortad livslängd.
Epidermolysis...
-
-
Learn more about epidermolysis bullosa (EB)
Chiesi Farmaceutici SpA, a leading international pharmaceutical company focused in the respiratory, neonatology and special care therapeutic areas, closed 2013 with a turnover of more than 1,236 million euro, an increase of 11,8% compared to 2012 (+14% at constant exchange rates).
"All...
-
Foster is a fixed combination of beclomethasone dipropionate (corticosteroid) and formoterol fumarate (a long-acting β2-agonist with rapid onset of effect) to be taken by inhalation. In 2006 the drug was approved for the maintenance therapy of asthma; after its first launch in Germany on...
-
The Lancet publishes the results of Chiesi Farmaceutici TRILOGY study, which shows one year data on the superior efficacy of the first extrafine fixed ICS/LABA/LAMA triple combination for COPD treatment compared with standard therapy.
The results of the study provide convincing support...Chiesi receives today the Certificate Top Employers Europe for the fourth year in a row. The prize is assigned only to those organisations that create optimal employee conditions, upon evaluation of the HR strategies and policies. The CRF Institute uses a proprietary method based on the HR...
Alberto, Paolo and Andrea Chiesi are the National winners of the EY “ L’Imprenditore dell’Anno 2015” Award. The prestigious recognition, promoted by EY-Ernst & Young and sponsored by Azimut Wealth Management, is now at its 19th edition. The...
-
Only 16% of those interviewed believe they may be at risk, even if the disease is considered serious or very serious in almost all cases (95%). On average 36% of those who claim to have heard about COPD make reference to the media (radio and TV in particular) as their main source...
Brussels, February 13, 2019 – Chiesi, an international research-focused healthcare Group (Chiesi Group), was awarded yesterday at the EURORDIS Black Pearl ceremony with the Company Award for Innovation. The EURORDIS Black Pearl Award is an annual event held in Brussels to recognise...
Paolo Chiesi receives the award for his long-standing commitment to vital treatment of the lungs of premature babies. The ceremony will take place on 10 May in Stockholm City Hall
Stockholm May 10, 2019 – Chiesi Farmaceutici, an international research-focused...
Market leader in respiratory innovation highlights potentially harmful[1] consequences of short-term thinking in rush to introduce policies to switch patients to so-called ‘green inhalers’ as they announce breakthrough environmentally friendly pressurised metered dose inhaler (pMDI)...
Chiesi Group Announces Establishment of New Global Rare Diseases Division
Specialized division focused on research and product development for rare and ultra-rare diseases highlights Chiesi’s commitment to building a brighter future for patients Chiesi Global Rare Diseases unit...-
CAMBRIDGE, Mass. and Parma, Italy – September 16, 2020 – Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients and Chiesi Farmaceutici S.p.A., an...
Tuesday morning, I attended the “Reducing the burden of asthma”, a joint ERS/Lancet session The session was initiated by Rebecca Craven, a deputy editor of The Lancet Respiratory Medicine(LRM). LRM have commissioned a series of papers to put more focus on the burden of asthma in...
Monday morning, I attended the session “Asthma pharmacology: clinical trials and mechanistic insights” – a very interesting session covering research on new biologicals in the treatment of severe asthma.
Mechanisms and physiology of asthma
Presented by Prof. Arnaud Bourdin
The asthma session started off with Prof. Arnaud Bourdin talking about mechanisms and physiology of asthma. Prof. Bourdin provided...
-
Parma (Italy), 10 May,...
Chiesi invites you to a webinar on "clinical and pathological features of mild asthma" on Thursday 24 June at 13.00-14.00 CET (14.00-15.00 EEST/Finland).
To register, please click here.
Chiesi is responsible for the costs of the...
-
-
-
-
-
Stockholm, October 16, 2023 - Chiesi, the international research-focused biopharmaceutical group, and the prestigious Karolinska Institutet (KI) have joined forces in a new collaborative research agreement. This partnership is focused on advancing the biological characterization of patients...
Aldrig tidigare har det varit så tydligt att alla måste bidra till att minska koldioxidutsläppen för att hejda den globala uppvärmningen. Därför väljer Chiesi att, i samarbete med Fly Green Fund, flyga på fossilfria bränslen.
För...
Stockholm, 6 November 2023 – Chiesi, an international research-focused biopharmaceutical group, announce today its collaboration with SweDeliver, a distinguished research and competence center specializing in drug delivery. This partnership represents a step forward in the pursuit of...
-
-
COPD is a lung disease that hits women harder than men: women develop it at a younger age, with less tobacco exposure and have a faster decline in lung function. COPD is also an under-diagnosed disease in both men and women. Early detection is essential so that actions can...
Parma, March 5th, 2024 - Chiesi Group announces the passing of Honorary President Dr. Paolo Chiesi a fundamental pillar of the company who shaped its history alongside his brother Alberto.
Born in Parma in 1940 and graduating in Chemistry and Pharmacy, he led the Corporate...
-
-
Chiesi Launch Initiative to Support Academic Research in Sweden
Chiesi Global Rare Disease is excited to announce and launch an academic request for proposal (RFP) for early-stage projects with clear therapeutic potential. The objective is to award funds to support...
Data från fas III-studien BRIGHT har publicerats i Journal of Inherited Metabolic Diseases. Studien undersökte säkerhet och effekt av pegunigalsidas alfa (2 mg/kg) administrerat var fjärde vecka under 52 veckor hos vuxna patienter med Fabrys sjukdom som tidigare behandlats...
-
-
